[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541331":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":50,"collaborators":20,"id":52,"slug":20,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":20,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"European Institute of Oncology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DWB-MRI","EXPERIMENTAL","Surveillance with diffusion whole body MRI",[13],"Diagnostic Test: Diffusion whole body MRI",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Diffusion whole body MRI","Diffusion whole body MRI protocol, consisting of sagittal T1-weighted and T2-weighted sequences on the whole spine, axial T1 weighted, T2-weighted and diffusion-weighted images from head to mid-thigh, performed on a 1.5 T scanner.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Monica Iorfida, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+390257489970","monica.iorfida@ieo.it",[31],{"facility":5,"status":32,"city":33,"state":20,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Milan","20141","Italy","IT",{"type":38,"coordinates":39},"Point",[40,41],9.18951,45.46427,{"lat":41,"lon":40},[44,45,49],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":46,"role":27,"phone":47,"phoneExt":20,"email":48},"Mara Negri","+390257489536","mara.negri@ieo.it",{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":51,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100541331",false,"NCT06328465","fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases","fREEDOM","Inclusion Criteria:\n\n* Pre or post-menopausal patient with histologically confirmed invasive breast cancer stage II - III HER2 + or TN operated breast carcinoma or patients underwent neoadjuvant treatment (included cT4d) with residual disease at definitive surgery\n* No evidence of distant metastases at baseline perioperative radiological staging (DWB-MRI, total body Computed Tomography (CT) or Positron Emission Tomography (PET\u002FCT) must be performed +\u002F- 1 month from surgery)\n* No relevant comorbidities\n* Eastern Cooperative Oncology Group (ECOG) performance status 0\n* Geographically accessible for follow up\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Absolute contraindications that exclude the execution of the MRI investigation, regardless of the clinical indication\n* Relative contraindications that include situations in which the innocuousness of the examination is not documented with certainty that therefore do not recommend the execution, except for serious indications related to the patient's clinical need\n* Older age (\\>75 years)\n* Previous or concomitant other malignancy except basal or squamous cell carcinoma of the skin or adequately treated in situ carcinoma of the cervix\n* Uncontrolled intercurrent illness including symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements","ALL","18 Years","75 Years",{"count":62,"type":63},145,"ESTIMATED","INTERVENTIONAL",[66],"NA","The aim of this study is to understand whether DWB-MRI (Diffusion Whole Body-Magnetic Resonance Imaging) is useful for early detection of locoregional or distant recurrence and whether early diagnosis influences the prognosis in high-risk populations thanks to the possibility of being able to use a more effective treatment. The primary objective is to evaluate 5-year overall survival (OS) in patients with Human Epidermal Growth Factor Receptor 2 positive (HER2+) or high-risk Triple Negative (TN) undergoing surveillance with DWB-MRI.",[69,70,71],"Invasive Breast Cancer","HER2-positive Breast Cancer","Triple Negative Breast Cancer",[69,70,71],"2026-01-02",{"date":75,"type":76},"2026-01-06","ACTUAL",{"date":78,"type":76},"2019-11-22",{"date":80,"type":63},"2028-12-31",{"name":5,"class":6},1]